Risperidone vs. Aripiprazole Safety in Adolescents

Comparative Safety Profiles

The American Academy of Child and Adolescent Psychiatry recommends that aripiprazole appears to have a more favorable safety profile than risperidone in adolescents, primarily due to lower risks of extrapyramidal symptoms and prolactin elevation, though both medications require careful monitoring for metabolic effects 1, 2, 3
Risperidone appears to be the most likely among atypical antipsychotics to produce extrapyramidal side effects in adolescents, according to the American Academy of Child and Adolescent Psychiatry 2, 3
Cases of extrapyramidal side effects, neuroleptic malignant syndrome, and tardive dyskinesia have been reported in teenagers taking risperidone, as noted by the American Academy of Child and Adolescent Psychiatry 3

Both aripiprazole and risperidone have demonstrated efficacy for treating irritability, hyperactivity, stereotypy, and social withdrawal in autism spectrum disorders, as reported by the American Academy of Child and Adolescent Psychiatry 1, 4
Risperidone showed a 69% positive response vs. 12% on placebo in autism spectrum disorders, according to the American Academy of Child and Adolescent Psychiatry 1
Aripiprazole showed a 56% positive response vs. 35% on placebo in autism spectrum disorders, as noted by the American Academy of Child and Adolescent Psychiatry 1

Regular neurological examination for extrapyramidal symptoms is recommended for both medications, according to the American Academy of Child and Adolescent Psychiatry 2, 3

Assessing risk factors for specific side effects, such as history of movement disorders, is crucial in deciding between aripiprazole and risperidone, as recommended by the American Academy of Child and Adolescent Psychiatry 5
Considering target symptoms, such as irritability and behavioral symptoms in autism spectrum disorders, is important in choosing between aripiprazole and risperidone, according to the American Academy of Child and Adolescent Psychiatry 1, 4